SEC Comment Letter 0000000000-25-003667 to Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc.
Date: April 4, 2025 · CIK: 0001422142 · Accession: 0000000000-25-003667
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286284
Letter
Re: Whitehawk Therapeutics, Inc. Registration Statement on Form S-3 Filed March 31, 2025 File No. 333-286284 Dear David Lennon:
April 4, 2025
David Lennon Chief Executive Officer Whitehawk Therapeutics, Inc. 2 Headquarters Plaza East Building, 11th Floor Morristown, NJ 07960
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Robert Wernli
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 4, 2025 David Lennon Chief Executive Officer Whitehawk Therapeutics, Inc. 2 Headquarters Plaza East Building, 11th Floor Morristown, NJ 07960 Re: Whitehawk Therapeutics, Inc. Registration Statement on Form S-3 Filed March 31, 2025 File No. 333-286284 Dear David Lennon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert Wernli </TEXT> </DOCUMENT>